NASDAQ:ISRG 7 December 2025 - 11 January 2026

Intuitive Surgical shares closed Friday at $586.24, up 0.2%, after Bernstein and Goldman Sachs raised their price targets to $740 and $714, respectively. The company will present at the J.P. Morgan Healthcare Conference on Jan. 14 and report Q4 earnings Jan. 22. Investors are focused on da Vinci 5 adoption and procedure growth. The stock’s 52-week range is $425 to $616.

Intuitive Surgical shares jumped 4.7% to $592.85 Tuesday, with trading volume topping 2.6 million shares. The stock now sits 3.8% below its 52-week high ahead of key company events on Jan. 14 and Jan. 22. Investors await management updates on demand and margins. U.S. economic data due Wednesday could influence rate-sensitive growth stocks.

Intuitive Surgical shares fell 1% to $560.61 in Friday’s afternoon trading, underperforming a mixed U.S. market on the first session of 2026. The move followed a management shift, with Chief Digital Officer Brian E. Miller taking a new role focused on digital and AI strategy. Medical-device stocks lagged, while broader healthcare edged higher. Investors are watching upcoming jobs and inflation data, plus the J.P. Morgan Healthcare Conference.

Intuitive Surgical shares fell 1.1% to $566.36 in the final 2025 trading session before U.S. markets closed for New Year’s Day. About 992,500 shares traded in a range between $565.77 and $573.28. The company’s next earnings call is set for Jan. 22. The S&P 500 ended the year down 0.74%, while the Nasdaq slipped 0.76%.

Intuitive Surgical shares fell about 2% to $548–$549 in late morning trading Tuesday, following a 3.17% rebound Monday that ended a five-day losing streak. The company’s market cap stood near $194 billion. Technical analysts noted the stock’s Relative Strength Rating rose to 81. Recent SEC filings showed mixed institutional activity, with Orion Portfolio Solutions increasing its stake and Nilsine Partners reducing holdings.

Intuitive Surgical shares rose 3.17% Monday to $559.52, snapping a five-day losing streak, then slipped to $558.09 in after-hours trading. An SEC Form 4 filing showed SVP Mark Brosius exercised and sold 4,964 shares last week under a 10b5-1 plan, totaling about $2.7 million.

Intuitive Surgical shares rose about 3% to near $558 on Dec. 15, 2025, amid heavy institutional-filing headlines and options market activity. SevenBridge Financial Group boosted its ISRG stake by 68.6%, while Silicon Valley Capital Partners cut its position by 96.5%. Texas Permanent School Fund and Neville Rodie & Shaw also trimmed holdings. Corient Private Wealth increased its stake by 68.8%.

Intuitive Surgical shares fell 4.3% this week, closing at $542.32 Friday after five straight declines. The drop followed FDA clearance expanding da Vinci SP’s U.S. indications, a Citigroup downgrade, a Wells Fargo price-target hike, and insider selling disclosures. ISRG now trades about 12% below its 52-week high.

Intuitive Surgical closed Friday at $542.32, down 0.92%, then traded nearly flat after hours. The stock moved amid a Citigroup downgrade to Neutral with a $635 target and a Wells Fargo target hike to $654. VP Mark Brosius filed to sell 5,276 shares under a 10b5-1 plan. Quantinno increased its stake, according to MarketBeat.